Temozolomide for the treatment of metastatic melanoma - Wikidata - wikimedia - TriplyDB

Temozolomide for the treatment of metastatic melanoma

Temozolomide for the treatment of metastatic melanoma

http://www.wikidata.org/entity/Q36852256

about

NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells Treatment patterns in patients with metastatic melanoma: a retrospective analysis.Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.Emerging options for the treatment of melanoma - focus on ipilimumab.Evaluation of surrogate tissues as indicators of drug activity in a melanoma skin model Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.Metastatic Melanoma presenting 24 years after surgical resection: a case report and review of the literature.Brain metastases as preventive and therapeutic targets.Trametinib in metastatic melanoma.Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application.The simulation of UV spectroscopy and electronic analysis of temozolomide and dacarbazine chemical decomposition to their metabolites.Lentigos, Melanocytic Naevi and Melanoma

P2860

Q29247923-DE1D1A07-1980-4240-834D-4ABD5016110B Q33634914-39545608-8010-4AE6-8F28-F9EF98F92D0D Q34362184-E882A0EB-9C7F-4757-A42A-F5FE871D071C Q35614792-F0535E6E-F6F9-46BA-94F4-9029DF2CBC1D Q36292634-DCB882E7-391E-4378-97E4-775B48798A3D Q37031656-BD8B4E0E-86D3-4AC8-8FAE-3BD695D4951C Q37148914-284C9EC3-CEFF-4ECC-B3D6-F950BFE4F8C2 Q37345234-A621F610-4D97-4DDB-82E9-EB188FEA49DD Q37437677-B9E1B472-9BED-456B-85FB-759D8B68853D Q37862581-2533421C-4509-42B3-988F-F63CE2908DB6 Q38536713-545E21B9-6F9B-4344-9328-A9A87E3722D4 Q42798738-9019BFA9-C0E8-47A5-BD8F-E71B134B6F2A Q51749901-77EDC361-54D2-41CB-80D4-D42821945D8A Q56828381-1D64C2EE-928B-4EBD-8411-2F7D8FF27D23

P2860

Temozolomide for the treatment of metastatic melanoma

http://www.wikidata.org/entity/Q36852256

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Temozolomide for the treatment of metastatic melanoma

@en

type

label

Temozolomide for the treatment of metastatic melanoma

@en

prefLabel

Temozolomide for the treatment of metastatic melanoma

@en

P1433

Q36852256-B3AB17B1-EDAC-44A3-8F63-F20162B8C5F2

P1476

Q36852256-1B0D2FA9-3F22-4944-B922-E21298573F1F

P2093

Q36852256-141126D2-5FE1-4363-B243-2F2A85750798

Q36852256-26C47D4E-DD76-44A1-B520-1188D9AF3A95

Q36852256-3BA1EAC4-DD6A-415B-98DC-0334ED8DED99

Q36852256-601984F0-3B1E-4508-A05F-1C710DFC7AA5

Q36852256-9C170365-7DA7-4D14-9D7D-F82ABCCCCECB

Q36852256-BAAA3605-B71D-4E3A-8A3B-141EC1CFFC5F

P2860

Q36852256-15F4D6A1-F9FF-4F92-A60B-1A3E3B55B23B

Q36852256-25435AA7-5635-4AF4-87FB-08E2A9E7C308

Q36852256-2C1DAF73-ABE6-4ED5-BC59-2BEADA946680

Q36852256-42CED149-FAAC-4D13-9A40-33CD0C8BE3A3

Q36852256-44581BBB-9AB1-4CD1-9907-E3B986308505

Q36852256-5DD8D137-3A5D-42E2-B756-AC5E26E6B073

Q36852256-64E7402E-2DAB-4EE5-AE7F-374E1B78AFD2

Q36852256-67D6A80B-774F-41CE-81B1-B1489A7851D6

Q36852256-722FB80D-157A-4D57-BB23-B3D7E684CE0B

Q36852256-8DE50C10-5FF9-4444-8D0D-8D410D1208A6

P304

Q36852256-C718318A-099B-4B40-B7A6-73A040D3AD1D

P31

Q36852256-BEC366F2-E369-47C3-99F5-1D5D7AE1A30D

P356

Q36852256-559D7071-2052-41BD-B64D-0A963202A32C

P433

Q36852256-287F48FA-1624-4B71-810C-CA12FAF230B1

P478

Q36852256-4A253DE3-5A4F-4332-877C-6ED58ECCA647

P577

Q36852256-8860382C-ED28-494D-BBDA-7B4D40E4599C

P5875

Q36852256-04F3B9C6-929E-428B-BDD5-F915AACCB44E

P698

Q36852256-DC14CB57-3589-419F-9421-7C8BB68788CF

P932

Q36852256-3FDD5590-2889-4E04-9DDE-CDCAB6C5A857

P356

P1433

Current Oncology

P1476

Temozolomide for the treatment of metastatic melanoma

@en

P2093

I Quirbt

http://www.w3.org/2001/XMLSchema#string

K Bak

http://www.w3.org/2001/XMLSchema#string

M Charette

http://www.w3.org/2001/XMLSchema#string

Members of the Melanoma Diseas ...... Program in Evidence-Based Care

http://www.w3.org/2001/XMLSchema#string

S Verma

http://www.w3.org/2001/XMLSchema#string

T Petrella

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I trial of temozolomide (CCRG 81045: M&B; 39831: NSC 362856)

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.

Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.

Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.

The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.

P304

27-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.2007.98

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

240107305

http://www.w3.org/2001/XMLSchema#string

P698

17576461

http://www.w3.org/2001/XMLSchema#string

P932

1891190

http://www.w3.org/2001/XMLSchema#string